{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T09:28:10Z","timestamp":1649150890916},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n          Hintergrund Aufgrund des bekannten positiven Effekts der Wundheilungsmodulation mit Bevacizumab (Avastin\u00ae) bei Trabekulektomie wurde in einer retrospektiven Studie die Sicherheit und Wirksamkeit der Wundmodulation mit Avastin nach kombinierter Kataraktoperation mit CyPass-Stent-Implantation untersucht.<\/jats:p><jats:p>\n          Methode Retrospektiv wurden die pr\u00e4-, intra- und postoperativen Daten nach 3 und 6 Monaten bei 484 Augen mit kombinierter Operation erhoben (n\u2009=\u2009187 ohne Avastin, n\u2009=\u2009297 mit Avastin). Sicherheitskriterien waren intraoperative Komplikationen und postoperative spaltlampenmikroskopische Befunde. Wirksamkeitskriterien waren Augeninnendruck (IOD) und Anzahl drucksenkender Medikamente.<\/jats:p><jats:p>\n          Ergebnisse Bez\u00fcglich der Alters- und Geschlechtsverteilung, der fr\u00fchpostoperativen Fibrinreaktion, der Augeninnendruck- und Medikationssenkung unterscheiden sich die beiden Gruppen (mit und ohne Avastin) nicht statistisch signifikant. In der Avastin-Gruppe zeigten sich 3 Monate postoperativ statistisch signifikant weniger Irisgewebsreaktionen als in der Vergleichsgruppe (Chi-Quadrat-Test: p\u2009=\u20090,02, n\u2009=\u200947\/128); nach 6 Monaten noch ein leichter Trend (Chi-Quadrat-Test: p\u2009=\u20090,15, n\u2009=\u200945\/125). Weitere Trends zugunsten der Avastin-Gruppe wurden f\u00fcr die Versagerquote mit 2 gegen\u00fcber 6% nach 3 Monaten (Chi-Quadrat-Test: p\u2009=\u20090,103, n\u2009=\u200950\/130) bzw. 4 und 10% nach 6 Monaten (Chi-Quadrat-Test: p\u2009=\u20090,106, n\u2009=\u200950\/130) und f\u00fcr den Anteil der Augen ohne erg\u00e4nzende drucksenkende Medikation mit 86 gegen\u00fcber 74% bzw. 68 vs. 56% (Chi-Quadrat-Test: 3 Monate: p\u2009=\u20090,053; 6 Monate: p\u2009=\u20090,12; n\u2009=\u200950\/130) ermittelt. F\u00fcr den Anteil der Augen, der postoperativ ohne erg\u00e4nzende\n\t\t\t\t\tdrucksenkende Medikation die Druckschwelle von \u2264\u200921\u2009mmHg erreicht, zeigte sich 3 Monate postoperativ mit 85 gegen\u00fcber 74% (Chi-Quadrat-Test: p\u2009=\u20090,099, n\u2009=\u200950\/130) und nach 6 Monaten mit 65 gegen\u00fcber 54% ebenfalls ein starker Trend zugunsten der Avastin-Gruppe (Chi-Quadrat-Test: p\u2009=\u20090,11, n\u2009=\u200950\/130).<\/jats:p><jats:p>\n          Schlussfolgerung Die Eingabe von Avastin in die Vorderkammer ist sicher, reduziert die Gewebsreaktionen der Iris und verbessert bis zu 6 Monate postoperativ die Effektivit\u00e4t in klinisch begrenztem Umfang.<\/jats:p>","DOI":"10.1055\/a-0972-1427","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T23:00:17Z","timestamp":1568242817000},"page":"1210-1219","source":"Crossref","is-referenced-by-count":1,"title":["Monozentrische, retrospektive, vergleichende Studie zur Sicherheit und Effektivit\u00e4t der Wundheilungsmodulation mit Bevacizumab nach kombinierter Kataraktoperation mit CyPass-Stent-Implantation"],"prefix":"10.1055","volume":"237","author":[{"given":"Helmut","family":"H\u00f6h","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Dietrich-Bonhoeffer-Klinikum, Neubrandenburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Holland","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Dietrich-Bonhoeffer-Klinikum, Neubrandenburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Medra","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Augenheilkunde, Dietrich-Bonhoeffer-Klinikum, Neubrandenburg"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.ophtha.2016.06.032","article-title":"Two-year COMPASS Trial results: supraciliary microstenting with phacoemulsification in patients with open-angle glaucoma and cataracts","volume":"123","author":"S Vold","year":"2016","journal-title":"Ophthalmology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jcrs.2012.10.040","article-title":"Early postoperative safety and surgical outcomes after implantation of a suprachoroidal micro-stent for the treatment of open-angle glaucoma concomitant with cataract surgery","volume":"39","author":"H Hoeh","year":"2013","journal-title":"J Cataract Refract Surg"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/IJG.0000000000000134","article-title":"Initial clinical experience with the CyPass Micro-Stent: safety and surgical outcomes of a novel supraciliary microstent","volume":"25","author":"H Hoeh","year":"2016","journal-title":"J Glaucoma"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s00347-013-2927-6","article-title":"Supraziliarer Mikrostent bei Offenwinkelglaukom \u2013 klinische Ergebnisse einer prospektiven Multicenterstudie","volume":"111","author":"S Grisanti","year":"2014","journal-title":"Ophthalmologe"},{"key":"ref5","first-page":"165","volume-title":"Erste klinische Erfahrungen mit dem CyPass-Mikrostent: Sicherheit und Operationsergebnisse eines neuen suprazili\u00e4ren Mikrostents","author":"H Hoeh","year":"2013"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1055\/s-0034-1368214","article-title":"Two-year clinical experience with the CyPass Micro-Stent: safety and surgical outcomes of a novel supraciliary micro-stent","volume":"231","author":"H Hoeh","year":"2014","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00347-017-0594-8","article-title":"Suprachoroidale minimalinvasive Glaukomchirurgie. Verfahren und klinische Ergebnisse","volume":"115","author":"C Erb","year":"2018","journal-title":"Ophthalmologe"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ajo.2015.02.018","article-title":"Supraciliary micro-stent implantation for open-angle glaucoma failing topical therapy: 1-year results of a multicenter study","volume":"159","author":"J Garcia-Feijoo","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"ref10","volume-title":"5-Jahresergebnisse nach CyPass-Stent-Implantation \u2013 Erste Interimsanalyse","author":"A Medra","year":"2018"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ophtha.2017.08.028","article-title":"Modulation of fibroblasts in conjunctival wound healing","volume":"125","author":"M Zada","year":"2018","journal-title":"Ophthalmology"},{"key":"ref12","first-page":"797","article-title":"Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma","volume":"5","author":"M R Sedghipour","year":"2011","journal-title":"Clin Ophthalmol"},{"issue":"01","key":"ref13","first-page":"CD009782","article-title":"Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery","author":"J W Cheng","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"S 01","key":"ref14","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1186\/s12886-015-0134-8","article-title":"Pathobiology of wound healing after glaucoma filtration surgery","volume":"15","author":"O Yamanaka","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.survophthal.2012.01.008","article-title":"Wound modulation after filtration surgery","volume":"57","author":"L K Seibold","year":"2012","journal-title":"Surv Ophthalmol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1076\/ceyr.27.2.35.15456","article-title":"Effect of growth factors on the activation of human Tenon\u02bcs capsule fibroblasts","volume":"27","author":"P O Denk","year":"2003","journal-title":"Curr Eye Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1167\/iovs.08-2441","article-title":"Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit","volume":"50","author":"F Memarzadeh","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1167\/iovs.08-2662","article-title":"Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery","volume":"50","author":"Z Li","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref19","first-page":"513","article-title":"[Expressions of vascular endothelial growth factor and its receptors in rat conjunctival fibroblasts]","volume":"48","author":"G W Cheng","year":"2012","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3928\/1542-8877-20060301-12","article-title":"Needle bleb revision of encapsulated filtering bleb with bevacizumab","volume":"37","author":"M Y Kahook","year":"2006","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/IJG.0b013e31815f5345","article-title":"Vascular changes after intra-bleb injection of bevacizumab","volume":"17","author":"M A Coote","year":"2008","journal-title":"J Glaucoma"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.ophtha.2008.06.009","article-title":"Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy \u2013 a pilot study","volume":"115","author":"D S Grewal","year":"2008","journal-title":"Ophthalmology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1167\/iovs.10-5669","article-title":"Antifibrotic activity of bevacizumab on human Tenon\u02bcs fibroblasts in vitro","volume":"51","author":"E C O\u02bcNeill","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/IJG.0b013e31821826b2","article-title":"Safety and efficacy of using off-label bevacizumab versus mitomycin C to prevent bleb failure in a single-site phacotrabeculectomy by a randomized controlled clinical trial","volume":"21","author":"S Sengupta","year":"2012","journal-title":"J Glaucoma"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1442-9071.2012.02798.x","article-title":"Bleb vascularity following post-trabeculectomy subconjunctival bevacizumab: a pilot study","volume":"40","author":"B E Chua","year":"2012","journal-title":"Clin Exp Ophthalmol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/bjophthalmol-2013-303966","article-title":"Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study","volume":"98","author":"E Vandewalle","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/eye.2015.182","article-title":"Evaluation the adjunctive use of combined bevacizumab and mitimycinc to trabeculectomy in management of recurrent pediatric glaucoma","volume":"30","author":"R A Mahdy","year":"2016","journal-title":"Eye (Lond)"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1097\/IJG.0000000000000202","article-title":"Short-term results of trabeculectomy using adjunctive intracameral bevacizumab: a randomized controlled trial","volume":"25","author":"G Fakhraie","year":"2016","journal-title":"J Glaucoma"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12325-008-0047-5","article-title":"Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma","volume":"25","author":"N Kitnarong","year":"2008","journal-title":"Adv Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/eye.2008.113","article-title":"Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients","volume":"23","author":"K S Cornish","year":"2009","journal-title":"Eye (Lond)"},{"key":"ref31","volume-title":"Retrospektive, vergleichende, monozentrische, Studie zur Sicherheit und Effektivit\u00e4t der Wundheilungsmodulation nach CyPass-Stent-Implantation mit Bevacizumab","author":"H Hoeh","year":"2018"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-0972-1427.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T23:51:10Z","timestamp":1602805870000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-0972-1427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,15]]},"published-print":{"date-parts":[[2020,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-0972-1427","relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]}}}